CAGGIANO v. TEVA PHARMACEUTICALS USA INC.

CourtDistrict Court, E.D. Pennsylvania
DecidedSeptember 9, 2020
Docket5:19-cv-03074
StatusUnknown

This text of CAGGIANO v. TEVA PHARMACEUTICALS USA INC. (CAGGIANO v. TEVA PHARMACEUTICALS USA INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
CAGGIANO v. TEVA PHARMACEUTICALS USA INC., (E.D. Pa. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA MARY E. CAGGIANO, et al,

Plaintiffs,

v. CIVIL ACTION NO. 19-3074 TEVA PHARMACEUTICALS USA, INC., et al,

Defendants.

MEMORANDUM OPINION

Schmehl, J. /s/JLS September 9, 2020

I. INTRODUCTION

Plaintiffs in this matter filed a Complaint against Defendant, Teva Pharmaceuticals, Inc. in the Court of Common Pleas of Montgomery County, Pennsylvania, setting forth two causes of action under Pennsylvania law: 1) breach of contract and 2) violation of the Pennsylvania Wage Payment and Collection Law, 43 P.S. § 206.1, et seq (“WPCL”). Defendant removed the matter to this Court, alleging that Plaintiffs’ claims of contractual entitlement to separation pay are “properly brought under and completely preempted by” ERISA Section 502(a). Plaintiffs filed a Motion to Remand, arguing that the Severance Benefit Plan upon which their claims are based is not a “plan” governed by ERISA. Teva opposes remand, arguing that Plaintiffs’ claims for benefits are based upon its Separation Benefits Plan (“SBP”), Supplemental Unemployment Benefits Plan (“SUB Plan”) and Transition Plan, which are all one plan governed by ERISA. A period of discovery was ordered regarding the relationship of the SBP, the SUB Plan and the Transition Plan to each other, and the parties filed supplemental briefing. For the reasons that follow, I will grant Plaintiffs’ motion and remand this matter back to the Court of Common Pleas of Montgomery County. II. BACKGROUND AND STATEMENT OF FACTS Teva provided Plaintiffs with benefits pursuant to a Separation Benefits Policy,

which sets out specific eligibility rules and a formula for calculating the amount of separation pay based on certain criteria. (ECF No. 1, pp. 42-45.) Pursuant to the SBP, “[a] full- or part-time US-based, non-union Teva employee” is eligible to receive separation pay in the case of, inter alia, “elimination of position” and/or “reduction in force.” (Id. at p. 1.) Plaintiffs are all former non-union, full-time employees of Teva whose positions were related to facilities management. (Complaint, ¶¶ 29, 33, 34.) Plaintiffs were terminated by Teva after it decided to contract facilities management duties to a service provider. (Id., at ¶¶ 39-42.) Plaintiffs claim that they are therefore entitled to separation pay pursuant to the SBP, which Teva refuses to pay.

III. LEGAL STANDARD 28 U.S.C. §1441(b) provides that “any civil action brought in a State court of which the district courts of the United States have original jurisdiction, may be removed by the defendant or the defendants, to the district court of the United States for the district and division embracing the place where such action is pending.” The district courts shall have original jurisdiction of all civil actions arising under the Constitution, laws, or treaties of the United States. 28 U.S.C. § 1331. In the case of a motion to remand, the court “must assume as true all factual allegations of the complaint.” Yellen v. Teledyne Cont’l Motors, Inc., 832 F.Supp.2d 490, 493 (E.D. Pa. 2011) (quoting Steel Valley Auth. V. Union Switch & Signal Div., 809 F.2d 1006, 1010 (3d Cir. 1987). The removal statute “is to be strictly construed against removal.” Samuel-Bassett v. KIA Motors Am., Inc., 357 F.3d 392, 396 (3d Cir. 2004). All doubts are to be resolved in favor of remand, and the moving party bears the burden of showing that federal jurisdiction exists, and that removal was proper.

Boyer v. Snap-On Tools Corp., 913 F.2d 108, 111 (3d Cir. 1990). ERISA is one of the areas of federal law where “Congress intended the complete preemption doctrine to apply to state law causes of action which fit within the scope of ERISA’s civil enforcement provisions.” Dukes v. U.S. Healthcare, Inc., 57 F.3d 350, 353 (3d Cir. 1995). Therefore, when a plaintiff’s complaint contains an action to recover benefits due under an employee benefit plan, this will be considered a federal action, regardless of the cause of action pled in the complaint. Id., 57 F.3d at 353 n.2, 354 (citations omitted). In this matter, Plaintiffs argue that the SBP is not an ERISA plan, and therefore, jurisdiction is not proper in federal court. Accordingly, the resolution of the motion to remand turns on whether or not the SBP is an ERISA plan.

III. DISCUSSION Plaintiffs’ motion to remand argues that they are entitled to separation pay pursuant to the SBP. In response, Teva asserts that Plaintiffs’ action challenges the denial of benefits under the SBP, which is a welfare benefit plan subject to the Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. § 1001 et seq, and that Plaintiffs’ state law claims are therefore preempted by ERISA. In their supplemental briefing, Plaintiffs argue that the SBP is not an ERISA plan, and therefore, their claims are not subject to this Court’s jurisdiction. For ERISA to govern a benefit arrangement, there are five factors that must be met. The benefit arrangement must be: 1) a plan, fund, or program; 2) established or maintained; 3) by an employer or employee organization; 4) for the purpose of providing qualifying benefits; 5) to participants or beneficiaries. Donovan v. Dillingham, 688 F.2d 1367, 1371 (11th Cir. 1982); accord Smith v. Hartford Ins. Grp., 6 F.3d 131, 136 (3d Cir.

1993). In the instant matter, the pertinent question is whether the SBP, together with the SUB and the Transition Plan, are a qualifying “plan” under ERISA. Teva contends that the SBP, SUB and Transition Plan are in fact “one Severance Plan.” (Dep. of Elaine McGee, pp. 14-17.) However, after a thorough review of the three documents in question, it is clear that they cannot be considered one plan. First, a detailed comparison of the three documents show that they contain multiple contradictions and discrepancies. The SUB Plan and Transition Plan both contain extremely detailed sections setting forth a seven-step process for participants to exercise their rights under the Plan. See Summary Plan Description for SUB and

Transition Plans, ECF No. 23, Exh. E, pp. 10-13. The SBP has no such procedure, merely stating that before providing severance to employees, managers must “obtain approval from their immediate supervisor(s), department Vice President and Human Resources.” ECF No. 23, Exh. B, p. 2. Similarly, the SUB Plan and the Transition Plan have a formal “Plan Administrator” to adjudicate claims and appeals (ECF No. 23, Exh. E, p. 13,) but the SBP only states generally that “these guidelines shall be administered by Teva Human Resources and such other person or persons as Teva shall delegate from time to time. . .” ECF No. 23, Ex. B, p. 4. The documents have different titles, different effective dates and different purposes. The SBP has an effective date of April 4, 2018, amending an earlier version dated January 1, 2018, and the SUB and Transition Plans are effective February 12, 2018. ECF No. 23, Exs. B and E. Further, the SBP does not contain a specific stated purpose,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
CAGGIANO v. TEVA PHARMACEUTICALS USA INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/caggiano-v-teva-pharmaceuticals-usa-inc-paed-2020.